Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in conjunction with the sale of Zington
Mandate

Vinge advises in conjunction with the sale of Zington

August 08, 2022

Vinge has advised Sobro and other shareholders in conjunction with sale of Zington to VASS Group, a leading actor within digital transformation with its head office in Spain.

With a base in Stockholm, Zington delivers business critical digital solutions and expert knowledge to several of Sweden’s largest companies. Zington’s turnover is approximately MSEK 370 and it has 230 employees.

The transaction is conditional upon approval by the salient competition authorities.

Vinge’s team primarily consisted of Johan Winnerblad, Carl Sander, Elsie Nassar and Ellinor Wargenbrant.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025